Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification
Reexamination Certificate
2011-06-28
2011-06-28
Chen, Stacy B (Department: 1648)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
C435S005000, C435S069100, C424S233100
Reexamination Certificate
active
07968340
ABSTRACT:
The present invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one modification which brings about a reduction in the antigenicity, its production and use.
REFERENCES:
patent: 5276136 (1994-01-01), Skubitz et al.
patent: 6491907 (2002-12-01), Rabinowitz et al.
patent: 7252997 (2007-08-01), Hallek et al.
patent: 7556965 (2009-07-01), Hallek et al.
patent: 2001/0031463 (2001-10-01), Kleinschmidt et al.
patent: 2002/0192823 (2002-12-01), Bartlett et al.
patent: WO 95/23867 (1995-09-01), None
patent: WO 96/00587 (1996-01-01), None
patent: WO 97/08298 (1997-03-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 99/67393 (1999-12-01), None
Anderson, “Human Gene Therapy,”Nature392:25-30 (1998).
Asokan et al., “AAV Does the Shuffle,”Nature Biotechnology24:158-160 (2006).
Buning et al., “Receptor Targeting of Adeno-Associated Virus Vectors,”Gene Therapy10:1142-1151 (2003).
Grifman et al.,“Incorporation fo Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids,”Molecular Therapy3:964-975 (2001).
Hogue et al., “Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation,”Journal of Virology73:7912-7915 (1999).
Huttner et al., “Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies,”Gene Therapy10:2139-2147 (2003).
Kmiec, “Gene Therapy,”American Scientist87:240-247 (1999 ).
Maass et al., “Recombinant Adeno-Associated Virus for the Generation of Autologous, Gene-Modified Tumor Vaccines: Evidence for a High Transduction Efficiency into Primary Epithelial Cancer Cells,”Human Gene Therapy9:1049-1059 (1998).
Maheshri et al., “Directed Evolution of Adeno-Associated Virus Yields Enhanced Gene Delivery Vectors,”Nature Biotechnology24:198-204 (2006).
Marshall, “Second Child in French Trial is Found to Have Leukemia,”Science299:320 (2003).
Meng et al., “Tumor Suppressor Genes as Targets for Cancer Gene Therapy,”Gene Therapy of Cancer Chapter1, pp. 3-18 (1999).
Mizukami et al., “Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein,”Virology217:124-130 (1996).
Moskalenko et al., “Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure,”Journal of Virology74:1761-1766 (2000).
Nicklin et al., “Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells,”Molecular Therapy4:174-181 (2001).
Perabo et al., “In Vitro Selection of Viral Vectors with Modified Tropism: The Adeno-Associated Virus Display,”Molecular Therapy8:151-157 (2003).
Qing et al., “Human Fibroblast Growth Factor Receptor 1 is a Co-Receptor for Infection by Adeno-Associated Virus 2,”Nature Medicine5:71-77 (1999).
Ried et al., “Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors,”Journal of Virology76:4559-4566 (2002).
Russell,“ Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects,”European Journal of Cancer30A:1165-1171 (1994).
Shi et al., “Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors,”Human Gene Therapy12:1697-1711 (2001).
Shi et al., “RGD Inclusion of VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism,”Molecular Therapy7:515-525 (2003).
Smith et al., “The Challenges of genome Sequence Annotation or ‘the Devil is in the Details’,”Nature Biotechnology, 15:1222-1223 (1997).
Spear et al., “Evidence for Two Nucleotide Sequence Orientations Within the Terminal Repetition of Adeno-Associated Virus DNA,”Journal of Virology24:627-634 (1977).
Starovasnik et al., “Structural Mimicry of a Native Protein by a Minimized Binding Domain,”Proc. Natl. Acad. Sci.USA 94:10080-10085 (1997).
Summerford et al., “Membrane Associated Heparan Sulfate Proteoglycan is a Receptor for Adeno-Associated Virus Type 2 Virions,”Journal of Virology72:1438-1445 (1998).
Summerford et al., “αVβ5 Integrin: A Co-receptor for Adeno-Associated Virus Type 2 Infection,”Nature Medicine5:78-82 (1999).
Tseng et al., “Evolutionary Model for Predicting Protein Function by Matching Local Surfaces: a Bayesian Monte Carlo Approach,” The Ninth Annual Conference on Research in Computational Molecular Biology, May 14-18, 2005.
Verma et al., “Gene Therapy—Promises, Problems and Prospects,”Nature389:239-242 (1997).
Wendtner et al., “Efficient Gene Transfer of CD40 Ligand into Primary B-CLL cells using recombinant Adeno-Associated Virus (rAAV) Vectors,”Blood100:1655-1661 (2002).
White et al., “‘Designer’ Gene Therapy May Target Specific Body Area,”Business News2:1-2 (2003).
White et al., “Targeted Gene Delivery to Vascular Tissue in Vivo by Tropism-Modified Adeno-Associated Virus Vectors,”Circulation109:513-519 (2004).
Wobus et al., “Monoclonal Antibodies Against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection,”Journal of Virology74:9281-9293 (2000).
Wu et al., “Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism,”Journal of Virology74:8635-8647 (2000).
Aumailley et al., “Identification of the Arg-Gly-Asp Sequence in Laminin A Chain as a Latent Cell-Binding Site Being Exposed in Fragment P1,”FEBS262:82-86 (1990).
Bartlett et al., “Targeted Adeno-Associated Virus Vector Transduction of Nonpermissive Cells Mediated by a Bispecific F (ab'γ)2Antibody,”Nature Biotechnology17:181-186 (1999).
Chapman et al., “Structure, Sequence, and Function Correlations Among Parvoviruses,” Virology 194:491-508 (1993).
Chiorini et al., “High-Efficiency Transfer of the T Cell Co-Stimulatory Molecular B7-2 to Lymphoid Cells Using High-Titer Recombinant Adeno-Associated Virus Vectors,”Human Gene Therapy6:1531-1541 (1995).
Cosset et al., “Targeting Retrovirus Entry,”Gene Therapy3:946-956 (1996).
Douglas et al., “Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors,”Nature Biotechnology14:1574-1578 (1996).
Girod et al., “Genetic Capsid Modifications Allow Efficient Re-Targeting of Adeno-Associated Virus Type 2,”Nature Medicine5:1052-1056 (1999).
Hermonat et al., “Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants,”Journal of Virology51:329-339 (1984).
Luo et al., “Preliminary X-Ray Crystallographic Analysis of Canine Parovirus Crystals,”J. Mol. Biol.200:209-211 (1988).
Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,”Human Gene Therapy5:793-801 (1994).
Krasnykh et al., “Generation of Recombinant Adenovirus Vectors With Modified Fibers for Altering Viral Tropism,”Journal of Virology70:6839-6846 (1996).
Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,”Current Topics in Microbiology and Immunology158:97-129 (1992).
Nimako et al., “Human Papillomavirus-Specific Cytotoxic T Lymphocytes in Patients with Cervical Intraepithelial Neoplasia Grade III,”Cancer Research57:4855-4861 (1997).
Ohno et al., “Cel
Girod Anne
Hallek Michael
Ried Martin
Chen Stacy B
Clark & Elbing LLP
Medigene AG
LandOfFree
Structural protein of adeno-associated virus with modified... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Structural protein of adeno-associated virus with modified..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Structural protein of adeno-associated virus with modified... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730583